Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia

JACC. Basic to Translational Science
Joel P GiblettStephen P Hoole

Abstract

Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury. It can reduce infarct size, ischemic left ventricular dysfunction, and myocardial stunning. GLP-1 receptor agonists have also been shown to reduce infarct size in myocardial infarction. The mechanism through which this protection occurs is uncertain but may include hijacking the subcellular pathways of ischemic preconditioning, modulation of myocardial metabolism, and hemodynamic effects including peripheral, pulmonary, and coronary vasodilatation. This review will assess the evidence for each of these mechanisms in turn. Challenges remain in successfully translating cardioprotective interventions from bench-to-bedside. The window of cardioprotection is short and timing of cardioprotection in the appropriate clinical setting is critically important. We will emphasize the need for high-quality, well-designed research to evaluate GLP-1 as a cardioprotective agent for use in real-world practice.

References

Oct 21, 1992·Molecular and Cellular Biochemistry·G D Lopaschuk, M Saddik
Feb 1, 1994·Current Problems in Cardiology·H Taegtmeyer
Feb 2, 1999·Circulation·C DepreH Taegtmeyer
Oct 22, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Thomas KriegJames M Downey
Jul 2, 2003·Regulatory Peptides·Kristine MortensenCathrine Orskov
Sep 10, 2004·The Journal of Pharmacology and Experimental Therapeutics·Lazaros A NikolaidisRichard P Shannon
Oct 23, 2004·American Journal of Physiology. Heart and Circulatory Physiology·Steen B KristiansenHans Erik Bøtker
May 12, 2005·Trends in Cardiovascular Medicine·Derek J HausenloyDerek M Yellon
Jun 14, 2005·Cardiovascular Research·Hajime KinJakob Vinten-Johansen
Jul 19, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Lazaros A NikolaidisRichard P Shannon
Feb 20, 2007·Pharmacology & Therapeutics·Máire E Doyle, Josephine M Egan
Aug 23, 2007·American Journal of Physiology. Endocrinology and Metabolism·Ananda BasuMichael J Joyner
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Aug 19, 2008·Archives of Biochemistry and Biophysics·Brian D GreenDavid J Grieve
Feb 7, 2009·Journal of the American College of Cardiology·Leo TimmersImo E Hoefer
Feb 27, 2009·Basic Research in Cardiology·Derek J HausenloyDerek M Yellon
Apr 24, 2009·European Journal of Heart Failure·Stephen P HooleDavid P Dutka
Oct 8, 2009·Circulation. Heart Failure·Derek J Hausenloy, Derek M Yellon
Jan 19, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Mads HalbirkHenrik Wiggers
Feb 1, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Susana RavassaJavier Díez
Sep 17, 2011·European Heart Journal·Jacob LønborgThomas Engstrøm

❮ Previous
Next ❯

Citations

Jul 1, 2020·Herz·Dirk Müller-WielandNikolaus Marx
Dec 12, 2018·Frontiers in Endocrinology·Jordan RowlandsRodrigo Carlessi
Dec 21, 2020·British Journal of Anaesthesia·Abraham H HulstJeroen Hermanides
Jan 13, 2021·Nature Metabolism·Fiona M Gribble, Frank Reimann
May 3, 2021·BMC Cardiovascular Disorders·Muhammad Aetesam-Ur-RahmanStephen P Hoole
Jan 25, 2019·Kidney International Supplements·Natalia A Rocha, Peter A McCullough

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Clinical Trials Mentioned

NCT01144338
NCT01179048
NCT01800968
NCT02127996
NCT02404376

Software Mentioned

EXAMINE
TECOS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.